Respiratory Diseases

Ensitrelvir fast track status is supported by phase 3 study findings showing resolution of COVID-19 symptoms a full day earlier in those taking the drug vs placebo.

Recent research shows that patients with mild-to-moderate COVID-19 who received ensitrelvir within 5 days of symptom onset saw their symptoms resolve a day earlier than those who received placebo.

For each of the 6 biologic agents FDA-approved for severe asthma, find the mechanism of action, indication, and biomarkers that predict enhanced response.

The burden of RSV-positive acute respiratory infections in older adults during the pre-COVID-19 period was substantial, according to findings from a Mayo Clinic team.

Your daily dose of clinical news you may have missed.

In most patients with viral respiratory infections, the chance of bacterial coinfection is low and antibiotics can be withheld safely, say authors of a new study.

Adding paired serology and sputum to nasal swab/nasopharyngeal swabs RT-PCR increased RSV detection by 50% to 66% on average, respectively.

Dupilumab in patients with uncontrolled COPD reduced annual exacerbations by 30%, a statistically significant and clinically meaningful outcome and a first for a biologic.

Delivered intranasally, the fully human anti-CD3 mAb Foralumab modulated T-cell inflammation in COVID-19 and may have wider application, say study authors.

AAAAI 2023. The TSLP inhibitor was superior to placebo in 2 post hoc analyses of the PATHWAY and NAVIGATOR clinical trials.

AAAAI 2023. Pandemic prescribing rates for systemic corticosteroids increased from Alpha to Delta to Omicron waves of COVID-19 but hospitalizations have dropped, study finds.

Pfizer will present pivotal phase 3 data for RSVpreF to the ACIP on February 23; FDA has set a PDUFA date for the vaccine candidate of August 2023.

Medical director of the NFID William Schaffner, MD, shares his messages to primary care clinicians as the final months of this year's flu season near.

Prediction of COPD exacerbations was significantly better with a CT biomarker-based model than either exacerbation history or BODE index.

Which states have the most residents reporting long COVID symptoms? Which ones have the least? Scroll through our new slideshow for answers.

Vaccine uptake this respiratory virus season is lagging compared to previous years, says Schaffner, medical director of the National Foundation for Infectious Diseases.

Check your knowledge of mechanistic features of severe asthma, specific biomarker level cut offs, and impact of comorbid disease on choice of biologic treatment.

The approval offers patients the choice to administer the monoclonal antibody at home using a prefilled device or to continue to receive it in a clinical setting.

COPD was associated with a 61% increase in risk of death and 13% greater total costs in the year after surgery, according to a new study.

Distinguishing between influenza, COVID-19, and RSV and persuading vaccine-weary patients to get vaccinated are some of the challenges this season, says William Schaffner, MD.

Asthma exacerbations in children living in low-income urban areas were significantly associated with reduced air quality and specific pollutants in a new analysis.

The mRNA vaccine returned efficacy of 83.7% against RSV-associated lower respiratory tract disease defined by ≥2 symptoms and of 82.4% against disease defined by ≥3 symptoms.

If approved, nirsevimab would be the first single-dose RSV preventative option for the broad newborn and infant population in the US.

Adherence to several different healthy eating patterns was associated with reduced risk for all- and specific-cause mortality in a large prospective cohort study with 36 years of follow-up.

Among the CDC vaccine advisory group's recommendations are adding COVID-19 vaccines to the Vaccine for Children program and allowing PCV20 shots for those who previously received PCV13.

The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus vaccine candidate, RSVpreF, for adults aged ≥60 years.

RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.

The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.

Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.